ProCE Banner Activity

Evolving Standards in HR+/HER2- Metastatic Breast Cancer: Optimizing Outcomes Through Precision Medicine and Real-world Insight

Clinical Thought

This commentary features an expert’s summary of the evolving standards and insights from real-world data to achieve optimized outcomes in the management of patients with HR-positive/HER2-negative metastatic breast cancer with preexisting comorbid conditions who are receiving concomitant medications.

Released: May 12, 2025

Expiration: November 11, 2025

Share

Provided by

Provided by Clinical Care Options, LLC., in partnership with Practicing Clinicians Exchange (PCE) and ProCE, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Partners

Practicing Clinicians Exchange, LLC

ProCE Banner

ProCE, LLC

ProCE Banner

Disclosure

Primary Author

Sara A. Hurvitz, MD, FACP: researcher: Arvinas, AstraZeneca, Boehringer Ingelheim, Celcuity, Dantari, G1 Therapeutics, Genentech/Roche, Gilead, Greenwich LifeSciences, Immunomedics, Jazz/Zymeworks, Lilly, Loxo, Novartis, Orinove, Orum, Pfizer, Puma, Radius, Sanofi, Seagen, Stemline/Menarini; data and safety monitoring board: Atossa.